Avenue Therapeutics Stock Cash And Equivalents
| ATXI Stock | USD 2.01 0.04 2.03% |
Avenue Therapeutics fundamentals help investors to digest information that contributes to Avenue Therapeutics' financial success or failures. It also enables traders to predict the movement of Avenue Stock. The fundamental analysis module provides a way to measure Avenue Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avenue Therapeutics stock.
Avenue | Cash And Equivalents |
Avenue Therapeutics Company Cash And Equivalents Analysis
Avenue Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Avenue Therapeutics Cash And Equivalents | 890 K |
Most of Avenue Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avenue Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avenue Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Avenue Therapeutics is extremely important. It helps to project a fair market value of Avenue Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Avenue Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avenue Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avenue Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Avenue Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Avenue Therapeutics has 890 K in Cash And Equivalents. This is 99.89% lower than that of the Pharmaceuticals sector and 99.8% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.97% higher than that of the company.
Avenue Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avenue Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avenue Therapeutics could also be used in its relative valuation, which is a method of valuing Avenue Therapeutics by comparing valuation metrics of similar companies.Avenue Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Avenue Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Avenue Therapeutics from analyzing Avenue Therapeutics' financial statements. These drivers represent accounts that assess Avenue Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Avenue Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.8B | 4.1B | 11.3B | 7.4B | 6.6B | 4.7B | |
| Enterprise Value | 1.8B | 4.1B | 11.3B | 7.4B | 6.6B | 4.7B |
Avenue Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avenue Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avenue Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Avenue Fundamentals
| Return On Equity | -5.35 | ||||
| Return On Asset | -2.01 | ||||
| Current Valuation | 1.25 M | ||||
| Shares Outstanding | 1.91 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 10.33 % | ||||
| Number Of Shares Shorted | 50.92 K | ||||
| Price To Earning | (10.52) X | ||||
| Price To Book | 1.47 X | ||||
| EBITDA | 4.05 M | ||||
| Net Income | (10.38 M) | ||||
| Cash And Equivalents | 890 K | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 1.2 M | ||||
| Debt To Equity | 23.40 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 4.63 X | ||||
| Cash Flow From Operations | (9.45 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | 24.78 X | ||||
| Target Price | 8.0 | ||||
| Beta | -0.18 | ||||
| Market Capitalization | 3.84 M | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (90.93 M) | ||||
| Working Capital | 654 K | ||||
| Current Asset | 111.05 K | ||||
| Current Liabilities | 4.67 M | ||||
| Net Asset | 1.85 M |
About Avenue Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avenue Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avenue Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avenue Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:Check out Avenue Therapeutics Piotroski F Score and Avenue Therapeutics Altman Z Score analysis. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.